2008 Clinical Practice Guidelines - Canadian Diabetes Association

More documents

Recommendations

Info

2008 CLINICAL PRACTICE GUIDELINES S18 A dosage of 850 mg BID for an average of 2.8 years significantly decreased progression to diabetes by 31%. In the DPP population, metformin did not have any significant effect in the older age group (≥60 years) and in less obese (body mass index [BMI]
early detection of type 2 diabetes on population-wide mortality risk in US males. Health Care Manag Sci. 1999;2:223-227. 5. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care. 2008;31:596-615. 6. Micucci S, Thomas H, Vohra J. The effectiveness of schoolbased strategies for the primary prevention of obesity and for promoting physical activity and/or nutrition, the major modifiable risk factors for type 2 diabetes: a review of reviews. Hamilton, ON: Public Health Research, Education and Development Program, Ministry of Health and Long-Term Care; 2002. Available at: http://old.hamilton.ca/phcs/ ephpp/Research/Full-Reviews/Diabetes-Review.pdf. Accessed September 1, 2008. 7. Daniel M, Green LW, Marion SA, et al. Effectiveness of community-directed diabetes prevention and control in a rural Aboriginal population in British Columbia, Canada. Soc Sci Med. 1999;48:815-832. 8. Simmons D, Voyle J, Swinburn B, et al. Community-based approaches for the primary prevention of non-insulin-dependent diabetes mellitus. Diabet Med. 1997;14:519-526. 9. Charles MA, Fontbonne A, Thibult N, et al. Risk factors for NIDDM in white population. Paris prospective study. Diabetes. 1991;40:796-799. 10. Eastman RC, Cowie CC, Harris MI. Undiagnosed diabetes or impaired glucose tolerance and cardiovascular risk. Diabetes Care. 1997;20:127-128. 11. Tuomilehto J, Knowler WC, Zimmet P. Primary prevention of non-insulin-dependent diabetes mellitus. Diabetes Metab Rev. 1992;8:339-353. 12. Tuomilehto J, Lindström J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350. 13. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. 14. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005;67:152-162. 15. Kosaka K. Diagnostic criteria for diabetes mellitus in Japan — from a report of the Japan Diabetes Society (JDS) Committee on the Diagnosis of Diabetes Mellitus, 1982. Diabetes Res Clin Pract. 1994;24(suppl):S59-S62. 16. WHO Expert Committee on Diabetes Mellitus. 2nd report. WHO Technical Report Series No.646. SFr 5. Geneva, Switzerland: World Health Organization;1980. 17. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care. 2003;26:977- 980. 18. Knowler WC, Hamman RF, Edelstein SL, et al; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005;54:1150-1156. 19. Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002; 359:2072-2077. 20. Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA. 2003;290: 486-494. 21. Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35: 1073-1078. 22. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-161. 23. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet. 2006;368:1096-1105. 24. DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551-1562. S19 PREVENTION OF DIABETES
Page 1: Canadian Publication Mail Agreement
Page 4 and 5: 2008 CLINICAL PRACTICE GUIDELINES i
Page 6 and 7: 2008 CLINICAL PRACTICE GUIDELINES i
Page 8 and 9: 2008 CLINICAL PRACTICE GUIDELINES v
Page 10 and 11: 2008 CLINICAL PRACTICE GUIDELINES v
Page 12: 2008 CLINICAL PRACTICE GUIDELINES x
Page 16 and 17: 2008 CLINICAL PRACTICE GUIDELINES S
Page 82 and 83:
2008 CLINICAL PRACTICE GUIDELINES S
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
show all

2008 Clinical Practice Guidelines - Canadian Diabetes Association

Create successful ePaper yourself

Delete template?

Save as template?